BIONTECH SE SPON. ADRS 1
Commented by Matthias Schomber on July 15th, 2026 | 08:45 CEST
AI, Oncology, and Defense: TeamViewer, BioNTech, and Antimony Resources—A Great Mix for Your Portfolio!
Created and published on behalf of Antimony Resources Corp.
The stock market is a place of extremes, and today we are looking at a trio—TeamViewer, BioNTech, and Antimony Resources—that comes from three different sectors. There is a German software pioneer that, after painful setbacks, is suddenly showing clear signs of life again. There is a once-celebrated vaccine hero pumping billions into a risky but revolutionary future in cancer therapy—while still holding a substantial cash reserve. And then there is a Canadian mineral explorer digging deep into the earth for a material without which our modern world would simply grind to a halt—one that is also crucial for the defense industry. It is precisely this mix of a software-AI turnaround, a biotech-oncology transformation, and mineral potential that makes the market so incredibly exciting. Join us on a journey through three fascinating corporate stories.
Read
Commented by Matthias Schomber on July 6th, 2026 | 07:00 CEST
Burry's Short Attack on Micron Technology, BioNTech's Radical Overhaul and Strategic Resources: a Still-Quiet Commodities Player!
While the AI boom continues to promise enormous profits, the first cracks are beginning to appear. High-profile investors are suddenly betting against some of Wall Street's former—and in some cases already fallen—favourites. Will Micron Technology stage a successful turnaround, or is a deeper correction still ahead? At the same time, Germany's biotech sector is undergoing a period of profound change. Cost-cutting programs worth billions of euros and sweeping strategic realignments are putting investors' conviction to the test. Away from the spotlight, a potentially transformative story is also unfolding in the commodities sector. Investors seeking early exposure to the long-term trend in industrial decarbonization may want to take a closer look at Strategic Resources. We examine three companies from three very different industries—each offering a distinct investment opportunity.
Read
Commented by Fabian Lorenz on June 24th, 2026 | 08:40 CEST
Alarm at BMW! Sell-off at BioNTech! Desert Gold Undervalued!
Alarm at BMW. First, the company shocked shareholders with a profit warning. Now, business in China has collapsed. Analysts are finally reacting by slashing their estimates and price targets. Is it time to buy now? From the perspective of GBC Research, Desert Gold is the stock to buy right now. The company is set to transition from an explorer to a gold producer this summer. Analysts see its intrinsic value well above current price levels. And what about BioNTech? The share has been trading sideways for months. The announcement of location closures has drawn heavy criticism. Shareholders are equally disillusioned. Could rival Moderna, of all companies, now bring hope to the workforce?
Read
Commented by Tarik Dede on June 24th, 2026 | 08:05 CEST
Innovation in Research: Opportunities at Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech
On social media, you can find all sorts of negative comments and memes about the Pfizer Corporation. One very popular one claims that the company—founded in New York by German immigrants (Karl Pfizer and Karl Erhart)—has never cured a single disease in its 177-year history. This is at least partly true, as Pfizer—particularly for chronic, widespread conditions like high blood pressure or high cholesterol—focuses on treating symptoms rather than the underlying causes. However, it is also true that during World War II, Pfizer was the world's first and largest mass producer of penicillin. Critics level this same accusation against many pharmaceutical companies. Nevertheless, there are numerous companies working on innovative approaches to truly defeat diseases and improve people's lives. And, of course, they also aim to make a lot of money in the process. That is why we are taking a look today at the stocks of Vertex Pharmaceuticals, BioNxt Solutions, and BioNTech.
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by Fabian Lorenz on May 29th, 2026 | 09:40 CEST
A 4,000% gain is not enough? SanDisk, BioNTech, and Standard Uranium
60% in one month, 600% in six months, and 4,000% in one year. Yet there is still no sign of a major correction in SanDisk's stock. Even now, analysts are still raising their price targets significantly and joining the bulls' camp. In contrast, the uranium sector is currently on the sidelines. This offers a chance for contrarian investors. After all, it can really only be a matter of time before the industry is rediscovered as an AI winner. One exciting stock is Standard Uranium. The CEO recently made a strong impression at an investor conference. And what about BioNTech? Investors are disappointed, but analysts are positive. Can the biotech company provide new momentum starting today with new data from its oncology pipeline?
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read
Commented by André Will-Laudien on May 20th, 2026 | 08:05 CEST
Takeover Candidates for 2026! The Life Sciences Sector Is Heating Up: Evotec, BioNxt Solutions, BioNTech, and Formycon in Focus!
In recent months, the stock market has focused primarily on high-tech and defence stocks. While this strategy may have worked well for investors in the short term, it has also pushed several life sciences stocks to levels that some consider overly depressed. The Hamburg-based drug discovery company Evotec has lost around 75% of its market value over the past three years, with similar declines seen at BioNTech, Formycon, and BioNxt Solutions. Yet some pipelines are indeed valuable and backed by years of research. For a buyer with deep pockets, this could represent an attractive opportunity, as much of the costly early-stage work has already been completed. We are looking at a sector that has been unjustly forgotten. Where do opportunities lie for risk-conscious investors?
Read
Commented by Nico Popp on May 12th, 2026 | 09:10 CEST
Biotech and the Efficiency Revolution: Why the Final Mile Matters Most for Novartis, BioNTech, and BioNxt
While biotech investors long believed that only the discovery of an entirely new molecule could pave the way for a billion-dollar exit, the current market reality paints a far more nuanced picture. Savvy investors and industry analysts are increasingly recognizing that the true bottleneck in modern medicine is no longer the discovery of active ingredients alone. Instead, the strategic focus is shifting toward bioavailability, targeted drug delivery, and improved patient compliance. This transformation is being accelerated by the looming patent cliff, which threatens the pharmaceutical industry with combined annual peak revenues of several hundred billion US dollars by 2030. We take a closer look at the market and highlight emerging opportunities.
Read
Commented by Fabian Lorenz on May 7th, 2026 | 08:55 CEST
Alarm bells are ringing at BioNTech! Billions at Hensoldt! Buying opportunity at North Arrow Minerals!
"Buy first, then kill," was how Tübingen Mayor Boris Palmer reacted to BioNTech's planned site closures. The reason is that, within this framework, virtually all sites of the recently acquired CureVac are set to be shut down. A CureVac co-founder has also made serious allegations, and BioNTech shares are declining. At the same time, there may be an opportunity for rising prices with a gold gem. While the gold price continues to consolidate, there are arguments in favour of an investment in North Arrow Minerals. The company has repositioned itself and is now focusing on an interesting gold project. Just a few kilometres away lies the multi-million-ounce Harmony Gold Kalgold open-pit mine. Meanwhile, Hensoldt has outperformed its industry peers, Rheinmetall and RENK, so far this year. Yesterday, it became clear that there are indeed good reasons for this. So, should investors buy now?
Read